These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20402381)

  • 21. Tocilizumab: a review of its use in the management of rheumatoid arthritis.
    Oldfield V; Dhillon S; Plosker GL
    Drugs; 2009; 69(5):609-32. PubMed ID: 19368420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.
    Haraoui B; Casado G; Czirják L; Taylor A; Bernasconi C; Reiss W; Caporali R
    Clin Exp Rheumatol; 2017; 35(6):899-906. PubMed ID: 28516886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
    Patel AM; Moreland LW
    Drug Des Devel Ther; 2010 Oct; 4():263-78. PubMed ID: 21116333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
    Ogata A; Atsumi T; Fukuda T; Hirabayashi Y; Inaba M; Ishiguro N; Kai M; Kawabata D; Kida D; Kohsaka H; Matsumura R; Minota S; Mukai M; Sumida T; Takasugi K; Tamaki S; Takeuchi T; Ueda A; Yamamoto K; Yamanaka H; Yoshifuji H; Nomura A;
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1354-62. PubMed ID: 25832859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab in the treatment of adult rheumatoid arthritis.
    Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
    Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
    Navarro G; Taroumian S; Barroso N; Duan L; Furst D
    Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
    Nishimoto N; Hashimoto J; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Murata N; van der Heijde D; Kishimoto T
    Ann Rheum Dis; 2007 Sep; 66(9):1162-7. PubMed ID: 17485422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
    Kawashiri SY; Kawakami A; Yamasaki S; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Ida H; Origuchi T; Ueki Y; Eguchi K
    Rheumatol Int; 2011 Apr; 31(4):451-6. PubMed ID: 20024554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.
    O'Mahony A; John MR; Cho H; Hashizume M; Choy EH
    J Transl Med; 2018 Jun; 16(1):156. PubMed ID: 29879987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
    Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
    Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis.
    Jones G; Ding C
    Clin Med Insights Arthritis Musculoskelet Disord; 2010 Dec; 3():81-9. PubMed ID: 21234291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
    Ogata A; Kato Y; Higa S; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):258-267. PubMed ID: 30427250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.
    Carlson JJ; Ogale S; Dejonckheere F; Sullivan SD
    Value Health; 2015 Mar; 18(2):173-9. PubMed ID: 25773552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo.
    Wright HL; Cross AL; Edwards SW; Moots RJ
    Rheumatology (Oxford); 2014 Jul; 53(7):1321-31. PubMed ID: 24609058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
    Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.